AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$PTN

PALATIN TECHNOLOGIES INC

Price · $PTNvia TradingView
AI sentiment · 7d1 articles
SEP 9net (bullish − bearish)SEP 15
Bullish
0
Neutral
1
Bearish
0
Insider · 30dAll trades →

No SEC Form 4 filings for $PTN in the last 30 days.

See all $PTN insider activity →
Top stories · $PTNMore →
SEP 15·investegate.co.ukLow

GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach.

Palatin Technologies (PTN), valued at $20M, is developing melanocortin-receptor drugs for rare obesity, following Rhythm Pharmaceuticals (RYTM) and Neurocrine Biosciences' successes in the space. PTN's programs aim to improve efficacy and tolerability, with clinical trials expected to start in late 2026 and 2027. The market's validation of MC4R targets and rare-obesity drugs could significantly impact PTN's valuation.

AUG 6·finanznachrichten.de

Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

The article says rare endocrine and obesity assets have drawn about $2.9B (Neurocrine to acquire Soleno) and $10.0B (Vertex to acquire Crinetics) in four months. It highlights Rhythm’s IMCIVREE revenue of $71.3M in Q2 2026 and discusses Palatin Technologies (PTN) developing next-gen MC4R-selective candidates with IND targets in Q4 2026 and H1 2027.

AUG 3·SEC EDGAR 8-K

PALATIN TECHNOLOGIES INC (PTN): Submission of Matters to a Vote of Security Holders

PALATIN TECHNOLOGIES INC (PTN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification

PTN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning PTN (PALATIN TECHNOLOGIES INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent PTN coverage spans financial news, sector analysis and corporate actions.

What's driving PTN

  • Potential future catalyst if Phase 1 data are positive, but no immediate price impact.

    investegate.co.uk · Sep 15, 2026

  • The article is a class-and-competition narrative, but it does provide PTN-specific development timelines and differentiation claims that can affect near-term sentiment.

    finanznachrichten.de · Aug 6, 2026

  • This is a routine shareholder-vote 8-K with no new operating or financial guidance, but it can affect near-term sentiment around governance and equity dilution expectations.

    SEC EDGAR 8-K · Aug 3, 2026

AlphAI scores every news story that mentions PTN with an AI model for sentiment and relevance, and aggregates insider trades from PALATIN TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PTN

Score
SEP 15$PTNLowinvestegate.co.uk

GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach.

Palatin Technologies (PTN), valued at $20M, is developing melanocortin-receptor drugs for rare obesity, following Rhythm Pharmaceuticals (RYTM) and Neurocrine Biosciences' successes in the space. PTN's programs aim to improve efficacy and tolerability, with clinical trials expected to start in late 2026 and 2027. The market's validation of MC4R targets and rare-obesity drugs could significantly impact PTN's valuation.

2 min read
AUG 6$PTNLowfinanznachrichten.de

Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

The article says rare endocrine and obesity assets have drawn about $2.9B (Neurocrine to acquire Soleno) and $10.0B (Vertex to acquire Crinetics) in four months. It highlights Rhythm’s IMCIVREE revenue of $71.3M in Q2 2026 and discusses Palatin Technologies (PTN) developing next-gen MC4R-selective candidates with IND targets in Q4 2026 and H1 2027.

7 min read
AUG 3$PTNLowSEC EDGAR 8-K

PALATIN TECHNOLOGIES INC (PTN): Submission of Matters to a Vote of Security Holders

PALATIN TECHNOLOGIES INC (PTN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification

2 min read

Related tickers

More in Biotechnology